Author:
,Chung Raymond T,Ghany Marc G,Kim Arthur Y,Marks Kristen M,Naggie Susanna,Vargas Hugo E,Aronsohn Andrew I,Bhattacharya Debika,Broder Tina,Falade-Nwulia Oluwaseun O,Fontana Robert J,Gordon Stuart C,Heller Theo,Holmberg Scott D,Jhaveri Ravi,Jonas Maureen M,Kiser Jennifer J,Linas Benjamin P,Lo Re Vincent,Morgan Timothy R,Nahass Ronald G,Peters Marion G,Reddy K Rajender,Reynolds Andrew,Scott John D,Searson Gloria,Swan Tracy,Terrault Norah A,Trooskin Stacey B,Wong John B,Workowski Kimberly A
Abstract
Abstract
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or research data. A major update was released electronically in September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance’s scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendations herein were developed by volunteer hepatology and infectious disease experts representing AASLD and IDSA and have been peer reviewed and approved by each society’s governing board.
Funder
American Association for the Study of Liver Diseases
Infectious Diseases Society of America
NIH
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)